Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Rite Aid Corporation (RAD), CVS Caremark Corporation (CVS), Walgreen Company (WAG): Is the Economy to Blame for Drugstore Chains’ Poor Earnings?

Page 1 of 2

It’s been a tough couple of years for drugstore chains. Rite Aid Corporation (NYSE:RAD) was close to bankruptcy in 2012, CVS Caremark Corporation (NYSE:CVS) recently paid $11 million to avoid civil charges due to prescription painkiller issues in its Oklahoma stores, and Walgreen Company (NYSE:WAG) had a battle with pharmacy benefits manager Express Scripts Holding Company (NASDAQ:ESRX) earlier this year. Yet, despite all of this, all three companies reported an increase in earnings in the most recent quarter.

Rite Aid Corporation (NYSE:RAD)

Walgreen Company (NYSE:WAG), likely assuming that investors would be disappointed that the results weren’t better, blamed the sluggish economy. While many analysts say the economy is on the way back, drugstore chains are located in a variety of neighborhoods, including those in low-income areas. Walgreen Company (NYSE:WAG)’s locations in these neighborhoods are showing slower sales, the company says.

Earnings up, shares down

Walgreen’s earnings were up 16% but the fine details of the chain’s earnings call brought shares down. Investors had expected a better result from the expiration of many patents that had once protected drugs like Lipitor from being made into generics. Since generics have a higher profit margin than prescriptions, shareholders expected big results from the change.

The drug retailer reported $624 million in earnings for the quarter, with a 3% increase in revenue, totaling $18.31 billion. Perhaps, the biggest concern for investors is that the sales increase was mostly isolated to the stores’ pharmacies, with front-end store sales sagging. The company’s CEO emphasized the company plans to focus on upping front-end sales in the next quarter through circulars and other promotions aimed at luring customers inside to shop.

Focusing on the positive

Front-end sales were also an issue in competitor CVS Caremark Corporation (NYSE:CVS)’ earnings report. The company’s net income increase of $180 million from a year earlier was largely attributed to the same generic availability Walgreen Company (NYSE:WAG) experienced. But, the good news was that CVS Caremark Corporation (NYSE:CVS)’ front-end sales increased 1.4% year over year in the recent quarter.

CVS’ expectations for the upcoming quarter wasn’t quite as positive, though. The company mentioned the sequestration, leading to spending cuts that will impact Medicare spending on prescriptions for older people. CVS Caremark Corporation (NYSE:CVS) division, which administers benefits for businesses and government agencies, is more closely impacted by changes to healthcare than retail chains.

Rite Aid close behind

Closing in on its competitors is Rite Aid Corporation (NYSE:RAD), once the underdog of the retail drugstore business. The company follows Walgreen and CVS Caremark Corporation (NYSE:CVS) Pharmacy, with $91 million in earnings in its recent quarter. Last year, at the same time, Rite Aid Corporation (NYSE:RAD) had experienced a loss due to a charge of $21 million due to a pending litigation.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!